Apricus Biosciences, Inc. , a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has begun enrolling patients in a Phase 2b clinical trial to evaluate Apricus' novel product candidate, fispemifene, a selective estrogen receptor modulator , for the treatment of men with symptomatic secondary hypogonadism also known as low testosterone. The Phase 2 proof-of-concept clinical trial is a randomized, double-blind, placebo-controlled, parallel arm, multi-center study in approximately 160 hypogonadal men aged 18 to 64 who present with sexual dysfunction related to secondary hypogonadism, or low levels of testosterone.